Amendment: SEC Form SC 13G/A filed by Praxis Precision Medicines Inc.
$PRAX
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2025 | $97.00 | Outperform | Oppenheimer |
| 5/7/2025 | $80.00 | Buy | Chardan Capital Markets |
| 3/3/2025 | $120.00 → $105.00 | Buy | H.C. Wainwright |
| 2/11/2025 | $111.00 | Buy | Deutsche Bank |
| 8/5/2024 | $134.00 | Outperform | Oppenheimer |
| 6/24/2024 | $145.00 | Buy | Needham |
| 6/18/2024 | $155.00 | Buy | Guggenheim |
| 5/1/2024 | $117.00 | Outperform | Robert W. Baird |
4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
4 - Praxis Precision Medicines, Inc. (0001689548) (Issuer)
SCHEDULE 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)
SCHEDULE 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)
SCHEDULE 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)
Oppenheimer resumed coverage of Praxis Precision Medicines with a rating of Outperform and set a new price target of $97.00
Chardan Capital Markets initiated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $80.00
H.C. Wainwright reiterated coverage of Praxis Precision Medicines with a rating of Buy and set a new price target of $105.00 from $120.00 previously
BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on August 1, 2025, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 3,875 shares of its common stock to three new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the em
BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that CEO Marcio Souza will be participating a virtual fireside chat hosted by Truist Securities analyst Joon Lee on August 5, 2025 at 10:00amEST. The registration link can be found here. About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characteriz
RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in seizure frequency from baseline, with 22% at 100% seizure reduction in last 28 days Initiated two registrational studies for Developmental and Epileptic Encephalopathies (DEEs) programs: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A Gain-of-Function (GoF) with elsunersen Relutrigine granted U.S. FDA Breakthrough Therapy Designation for the treatment of seizures associated with SCN2A and SCN8A DEEs, enabling expedited development Cash and investments of approximately $447 million as of June 30, 2025 maintains runway into 2028 Praxi
PRAX-944 Phase 2b Essential1 Study topline results expected in 4Q22; primary endpoint updated to efficacy PRAX-562 Phase 1 study completed, confirming biomarker change and potential for wide therapeutic window Cash and investments of $165.4 million as of June 30, 2022 supports runway into 1Q24 BOSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the second quarter of 2022
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the appointment of Jill DeSimone to its board of directors. "We are very excited to have Jill join the Praxis board of directors. She is an ideal fit for the Praxis board with her impressive background as a global business leader for multi-billion-dollar products, unique insights into product strategy and portfolio prioritization, and breadth of experience advocating for excellence
BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced the appointment of Megan Sniecinski as chief business officer and provided key updates on members of the executive leadership team. Praxis has promoted Alyssa Wyant to chief regulatory and quality officer and Karl Hansen, Ph.D., to chief technical operations officer. In addition, chief scientific officer and co-founder, Steven Petrou, Ph.D., has decided to fully dedicate his time to Praxis upon stepping
SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)
SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)
SC 13G/A - Praxis Precision Medicines, Inc. (0001689548) (Subject)
RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in seizure frequency from baseline, with 22% at 100% seizure reduction in last 28 days Initiated two registrational studies for Developmental and Epileptic Encephalopathies (DEEs) programs: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A Gain-of-Function (GoF) with elsunersen Relutrigine granted U.S. FDA Breakthrough Therapy Designation for the treatment of seizures associated with SCN2A and SCN8A DEEs, enabling expedited development Cash and investments of approximately $447 million as of June 30, 2025 maintains runway into 2028 Praxi
Dosing with vormatrigine over 8 weeks led to 56.3% median reduction in seizure frequency Approximately 22% of patients reached 100% reduction in seizure frequency in the last 28 days on treatment Rapid and sustained response, with over 54% of patients achieving 50% response in the first week Vormatrigine was generally well tolerated and continues to demonstrate favorable safety profile BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitati
BOSTON, July 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report topline results from the RADIANT trial of vormatrigine and its financial results from the second quarter ended June 30, 2025, before the financial markets open on Monday, August 4, 2025. The Company will host a live webcast the same morning at 8:30am ET, which can be accessed by visiting this registration link. This live webcast will also be available through th